Nearly half achieved no detectable cancer at all
For patients whose aggressive T-cell lymphomas have resisted every prior treatment, the path to a stem cell transplant has long been blocked by a cruel paradox: the disease must first be controlled before the body can survive the cure. A research team at Mass General Brigham has now published evidence that combining two existing drugs — duvelisib and romidepsin — may help break that deadlock, achieving meaningful remission in a majority of patients and opening a door that had, for many, appeared permanently closed. The findings, grounded in real clinical practice rather than idealized trial conditions, suggest that medicine is slowly learning to navigate one of oncology's more stubborn impasses.
- Relapsed and refractory T-cell lymphomas are among the most treatment-resistant blood cancers, leaving patients with few options and a transplant pathway that requires disease control they cannot achieve.
- Across 38 real-world patients, the duvelisib-romidepsin combination shrank or eliminated cancer in 61% of cases — with 47% reaching undetectable disease — numbers that stand out sharply against the historical record for this disease.
- Eleven patients crossed the critical threshold and received stem cell transplants, the very outcome that had seemed out of reach, while one subtype responded at an 82% rate.
- One patient died from treatment-related complications, a reminder that even a promising combination carries genuine risk and demands careful clinical judgment.
- Researchers are now pushing toward personalization — seeking non-invasive ways to predict who will respond before treatment begins — while also working to persuade insurers and regulators to expand access.
When a T-cell lymphoma resists or relapses after initial treatment, options narrow fast. These aggressive blood cancers — peripheral and cutaneous varieties — tend to resist standard therapy, and patients who might benefit from stem cell transplants face a difficult catch-22: the disease must be controlled before the body can survive the transplant itself. For years, that bottleneck has left many people trapped.
A team at Mass General Brigham, working through the PETAL Consortium, set out to test whether two existing drugs used together might change that. They administered duvelisib and romidepsin to 38 patients with relapsed or refractory T-cell lymphomas and tracked outcomes carefully. The results, published in Blood Advances, were encouraging: 61 percent of patients saw their cancer shrink or disappear, and nearly half achieved no detectable disease at all. Eleven went on to receive stem cell transplants. In one subtype — nodal T-follicular helper cell lymphoma — the response rate reached 82 percent.
What distinguishes this study is its rootedness in real clinical practice. Researchers tracked outcomes across diverse patient populations, with all the complications that entails: dose adjustments, treatment interruptions, variable side-effect management. The combination proved tolerable under these conditions — though one patient died from treatment-related complications, a sobering counterweight to the otherwise promising data.
Clinical research coordinator Josie Ford noted that real-world evidence fills a gap left by earlier controlled trials. Hematologist Salvia Jain framed the findings as a potential lever for expanding access, arguing that demonstrated efficacy and manageable safety can shift conversations with insurers and regulators. The next step, Jain suggested, is personalization — identifying in advance, through non-invasive monitoring, which patients are most likely to respond, sparing others unnecessary risk. For now, the combination offers a concrete option where few existed before.
When a T-cell lymphoma comes back after initial treatment, or never responds to it in the first place, the options narrow quickly. These are aggressive blood cancers—peripheral and cutaneous varieties—that tend to shrug off standard therapy. Patients who might benefit from stem cell transplants face a catch-22: the disease has to be controlled first, brought low enough that the body can survive the transplant itself. For years, this bottleneck has trapped people in a difficult position, their cancer resistant and their path forward blocked.
A team at Mass General Brigham, working through the PETAL Consortium, decided to test whether two existing drugs used in combination might crack this problem. They gave duvelisib and romidepsin together to 38 patients with relapsed or refractory T-cell lymphomas and tracked what happened: whether tumors shrank, whether patients lived longer, what side effects emerged. The results, published in Blood Advances, suggest the pairing works.
In 61 percent of the patients studied, the cancer shrank or disappeared entirely. Nearly half—47 percent—achieved no detectable cancer at all. Eleven of these patients went on to receive stem cell transplants, the very milestone that had seemed out of reach. In one particular subtype, nodal T-follicular helper cell lymphoma, the response rate climbed to 82 percent. These are substantial numbers for a disease that has historically been difficult to move.
What makes this study different from earlier trials is its grounding in real clinical practice. Researchers didn't work in a controlled lab setting with ideal patients. They tracked how the drugs actually performed in diverse populations, with all the messiness that entails: dose adjustments, treatment interruptions, variations in how different clinics managed side effects. The drug combination proved tolerable even under these less-than-ideal conditions. Most patients experienced manageable adverse effects. One patient, however, died from complications related to the treatment itself—a sobering reminder that even promising therapies carry risk.
Josie Ford, the clinical research coordinator who led the analysis, noted that the real-world data fills a gap left by earlier trials. It shows not just whether the drugs work in theory, but whether they work when deployed across different settings and patient populations. Salvia Jain, a hematologist and founding member of the PETAL consortium, framed the findings as a potential gateway to broader access. Insurance companies and regulatory agencies have been cautious about approving new combinations, but evidence like this—showing both efficacy and manageable safety—can shift those conversations.
The next frontier, Jain suggested, lies in personalization. Researchers want to identify which patients will respond well and which won't, ideally through non-invasive monitoring rather than repeated biopsies. If they can predict who benefits before starting treatment, they can spare others unnecessary exposure to side effects and focus resources on those most likely to succeed. For now, the combination of duvelisib and romidepsin stands as a concrete option for patients whose lymphomas have otherwise run out of answers.
Citações Notáveis
These findings support duvelisib and romidepsin's efficacy, safety and tolerability, and we hope the study facilitates improved access to the treatment through insurance coverage and regulatory agency approvals.— Dr. Salvia Jain, hematologist and medical oncologist at Mass General Hospital
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that this is a "real-world" study rather than just another clinical trial?
Clinical trials are usually tightly controlled—specific patients, specific doses, specific settings. Real-world data shows what actually happens when a doctor uses the drugs in a busy hospital with patients who have other conditions, who miss doses, whose bodies respond differently. It's messier, but it's honest.
So the 61 percent response rate—is that good?
For an aggressive cancer that's already beaten standard therapy? Yes. Most of these patients had nowhere else to go. And nearly half got to a point where doctors couldn't detect cancer anymore. That opens the door to transplant.
What about that patient who died?
One death in 38 patients is a real loss, and it matters. It's why the researchers are transparent about it. These drugs are powerful. They work, but they're not harmless.
Why focus on the T-follicular helper subtype separately?
Because it responded at 82 percent—much higher than the overall 61 percent. That's a signal. It suggests the combination might work better for some lymphomas than others. That's the kind of pattern that could eventually let doctors match drugs to patients.
What's the next step?
Getting insurance companies and regulators to approve it. And figuring out how to predict who will respond before you start treatment. Right now it's trial and error. If they can narrow that down, fewer patients suffer through ineffective therapy.